Literature DB >> 15956406

Analysis of Bordetella pertussis populations in European countries with different vaccination policies.

S C M van Amersfoorth1, L M Schouls, H G J van der Heide, A Advani, H O Hallander, K Bondeson, C H W von König, M Riffelmann, C Vahrenholz, N Guiso, V Caro, E Njamkepo, Q He, J Mertsola, F R Mooi.   

Abstract

Despite the widespread use of pertussis vaccines during the last decades, pertussis has remained an endemic disease with frequent epidemic outbreaks. Currently two types of vaccines are used: whole-cell vaccines (WCVs) and recently developed acellular vaccines (ACVs). The long-term aim of our studies is to assess the effect of different vaccination policies on the population structure of Bordetella pertussis and ultimately on the disease burden in Europe. In the present study, a total of 102 B. pertussis isolates from the period 1998 to 2001 from five European countries (Finland, Sweden, Germany, The Netherlands, and France) were characterized. The isolates were analyzed by typing based on variable number of tandem repeats (VNTR); by sequencing of polymorphic genes encoding the surface proteins pertussis toxin S1 and S3 subunits (ptxA and ptxC), pertactin (prn), and tracheal colonization factor (tcfA); and by fimbrial serotyping. The results reveal a relationship between geographic location and VNTR types, the frequency of the ptxC alleles, and serotypes. We have not observed a relationship between the strain characteristics we studied and vaccination programs. Our results provide a baseline which can be used to reveal changes in the B. pertussis population in Europe in the coming years.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15956406      PMCID: PMC1151907          DOI: 10.1128/JCM.43.6.2837-2843.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  31 in total

Review 1.  Overview of recent clinical trials of acellular pertussis vaccines.

Authors:  E Miller
Journal:  Biologicals       Date:  1999-06       Impact factor: 1.856

2.  Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999.

Authors:  P Cassiday; G Sanden; K Heuvelman; F Mooi; K M Bisgard; T Popovic
Journal:  J Infect Dis       Date:  2000-10-09       Impact factor: 5.226

3.  Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years.

Authors:  C Weber; C Boursaux-Eude; G Coralie; V Caro; N Guiso
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

4.  Thirty-five years' experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity.

Authors:  E Njamkepo; F Rimlinger; S Thiberge; Nicole Guiso
Journal:  Vaccine       Date:  2002-01-31       Impact factor: 3.641

5.  Multilocus sequence typing of Bordetella pertussis based on surface protein genes.

Authors:  Inge H M van Loo; Kees J Heuvelman; Audrey J King; Frits R Mooi
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

Review 6.  Systematic review of the effects of pertussis vaccines in children.

Authors:  Tom Jefferson; Melanie Rudin; Carlo DiPietrantonj
Journal:  Vaccine       Date:  2003-05-16       Impact factor: 3.641

7.  Changes in the Dutch Bordetella pertussis population in the first 20 years after the introduction of whole-cell vaccines.

Authors:  Inge H M van Loo; Frits R Mooi
Journal:  Microbiology       Date:  2002-07       Impact factor: 2.777

8.  Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution.

Authors:  F R Mooi; H van Oirschot; K Heuvelman; H G van der Heide; W Gaastra; R J Willems
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

9.  Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines.

Authors:  P Olin; F Rasmussen; L Gustafsson; H O Hallander; H Heijbel
Journal:  Lancet       Date:  1997-11-29       Impact factor: 79.321

10.  Bordetella pertussis isolates with a heterogeneous phenotype for erythromycin resistance.

Authors:  K E Wilson; P K Cassiday; T Popovic; G N Sanden
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

View more
  31 in total

1.  Antigenic divergence of Bordetella pertussis isolates in Taiwan.

Authors:  Shu-Man Yao; Yu-Chi Lin; Chen-Ying Chou; Ying-Yan Chen; Miao-Ju Hsiao; Hour-Young Chen; Jer-Jea Yan; Hsun-Pi Su; Shu-Ying Li
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

2.  Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains.

Authors:  Olga Borisova; Svetlana Yu Kombarova; Nelli S Zakharova; Marjolein van Gent; Vladimir A Aleshkin; Isabella Mazurova; Frits R Mooi
Journal:  Clin Vaccine Immunol       Date:  2007-01-03

3.  Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis.

Authors:  Hans Hallander; Abdolreza Advani; Marion Riffelmann; Carl H W von König; Valerie Caro; Nicole Guiso; Frits R Mooi; Anna Gzyl; Margit S Kaltoft; Norman K Fry; Jussi Mertsola; Qiushui He
Journal:  J Clin Microbiol       Date:  2007-08-15       Impact factor: 5.948

4.  Changes in genetic diversity of the Bordetella pertussis population in the United Kingdom between 1920 and 2006 reflect vaccination coverage and emergence of a single dominant clonal type.

Authors:  David J Litt; Shona E Neal; Norman K Fry
Journal:  J Clin Microbiol       Date:  2009-01-21       Impact factor: 5.948

5.  Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model.

Authors:  Eiji Komatsu; Fuminori Yamaguchi; Akio Abe; Alison A Weiss; Mineo Watanabe
Journal:  Clin Vaccine Immunol       Date:  2010-03-31

6.  Strain variation among Bordetella pertussis isolates circulating in Poland after 50 years of whole-cell pertussis vaccine use.

Authors:  Ewa Mosiej; Ewa Augustynowicz; Monika Zawadka; Waldemar Dabrowski; Anna Lutyńska
Journal:  J Clin Microbiol       Date:  2011-02-09       Impact factor: 5.948

7.  Strain variation and antigenic divergence among Bordetella pertussis circulating strains isolated from patients in Iran.

Authors:  Fatemah Sadeghpour Heravi; Vajihe Sadat Nikbin; Masomeh Nakhost Lotfi; Pouran Badiri; Nazanin Jannesar Ahmadi; Seyed Mohsen Zahraei; Fereshteh Shahcheraghi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-08-09       Impact factor: 3.267

8.  Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009.

Authors:  Abdolreza Advani; Hans O Hallander; Tine Dalby; Karen Angeliki Krogfelt; Nicole Guiso; Elisabeth Njamkepo; Carl Heinz Wirsing von Könnig; Marion Riffelmann; Frits R Mooi; Per Sandven; Anna Lutynska; Norman K Fry; Jussi Mertsola; Qiushui He
Journal:  J Clin Microbiol       Date:  2012-11-21       Impact factor: 5.948

9.  Sequence variation in virulence-related genes of Bordetella pertussis isolates from Poland in the period 1959-2013.

Authors:  E Mosiej; M Zawadka; K Krysztopa-Grzybowska; M Polak; E Augustynowicz; K Piekarska; A Lutyńska
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-08-05       Impact factor: 3.267

10.  Surveillance of Circulating Bordetella pertussis Strains in Europe during 1998 to 2015.

Authors:  Alex-Mikael Barkoff; Jussi Mertsola; Denis Pierard; Tine Dalby; Silje Vermedal Hoegh; Sophie Guillot; Paola Stefanelli; Marjolein van Gent; Guy Berbers; Didrik F Vestrheim; Margrethe Greve-Isdahl; Lena Wehlin; Margaretha Ljungman; Norman K Fry; Kevin Markey; Kari Auranen; Qiushui He
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.